The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers

Reviewed 6 sourcesPublished by PepVault

The Wegovy pill is daily semaglutide, FDA approved in December 2025. How to take it, its doses beside the weekly shot's, and OASIS 4 next to STEP 1.

A white-haired man in a cobalt tank top drinking a glass of water in a white kitchen, oats and an orange on the counter
Last reviewed
Sources
6
Questions
7
Compounds
2

The short answer

The Wegovy pill is semaglutide, the drug in the Wegovy shot, as a once-daily tablet, FDA approved for adults on December 22, 2025. The label's routine: one tablet each morning on an empty stomach with up to 4 ounces of plain water, then wait at least 30 minutes before food, drinks or other pills. In its 64-week trial, weight fell 13.6% on average at 25 mg, against 2.4% on placebo.

Every number checked at its primary source · · 6 sources · How we research

Evidence: Strong: two large randomized, placebo-controlled phase 3 trials (OASIS 4 for the tablet, STEP 1 for the injection) and the FDA labels; no trial has compared the pill and the shot head to head.

A white-haired man in a cobalt tank top drinking a glass of water in a white kitchen, oats and an orange on the counter

What is the Wegovy pill?

It is the same molecule as the weekly Wegovy injection, semaglutide, in a tablet. Semaglutide copies GLP-1, a gut hormone that helps set appetite and how much is eaten; it is 94% identical to the body's own GLP-1 and switches on the same receptor1. FDA approved Wegovy tablets on December 22, 20255. As of November 2026 the label approves them, beside a lower-calorie diet and more activity, for weight loss and keeping it off in adults with obesity, or overweight with a weight-related condition, and for lowering heart risk in adults with heart disease and obesity or overweight1. The injection's uses in children 12 and older and in the liver disease MASH do not extend to the tablets1.

The hard part of a semaglutide pill is that the stomach breaks peptides down and barely lets them through. The tablet carries salcaprozate sodium (SNAC), which the label calls an absorption enhancer: an ingredient that helps semaglutide cross the stomach lining, where most of it is absorbed1. Even so, only about 1% to 2% of each tablet's semaglutide reaches the blood, against 89% of an injected dose1. That gap is why the pill's top dose is 25 mg and the shot's usual one 2.4 mg.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault can remind you each morning at the time you set and log each tablet with one tap, so a skipped day is plain to see.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How do you take the Wegovy pill?

Because so little gets in, the label sets a morning routine around the tablet. In absorption studies with semaglutide tablets, a longer wait before eating let more in, and 50 mL of water let in more than 240 mL (a full glass), while 50 and 120 mL made no real difference12.

What you need

  • The tablet
  • A glass with no more than 4 ounces (half a cup) of plain water
  • 30 minutes before breakfast, coffee or other pills

The label's steps1:

  1. Take the tablet first thing in the morning, on an empty stomach, before you eat or drink anything.
  2. Swallow one tablet whole with up to 4 ounces of plain water. No coffee, tea, juice or other drink with it, and do not split, crush or chew it.
  3. Wait at least 30 minutes before you eat, drink anything else or take your other pills; a longer wait lets more in.
  4. Take only one tablet a day. If you miss a day, the label says to skip it and take the next tablet the following day, not two at once.
  5. Keep the tablets in their original bottle at room temperature, 68°F to 77°F.
A morning timeline: the tablet with up to 4 oz of water on waking, then a 30-minute band with nothing by mouth, then breakfast, coffee and other pills
Look at the shaded band: the 30 minutes after the tablet are for nothing else.

Other medicines by mouth: semaglutide slows the stomach, and in a study with the semaglutide tablet the level of levothyroxine (a thyroid medicine) came out 33% higher1. The label asks the prescriber to watch such medicines, so name every pill you take.

PepVault can remind you each morning at the time you set and log each tablet with one tap, so a skipped day is plain to see. Set reminders in PepVault

PepVault's weight log and side-effect log keep the numbers and the queasy days together for the prescriber at each step-up. Track your weight in PepVault

How does the pill's label differ from the shot's?

Both sit on one Wegovy label, side by side1. The pill climbs a month at a time over 90 days; the shot climbs every 4 weeks over 161.

LabelWegovy pillWegovy shot
How oftenOnce a day, in the morning1Once a week, same weekday, any time of day1
Food and waterEmpty stomach, up to 4 oz of plain water, 30 minutes before anything else1With or without meals1
Starting dose1.5 mg a day, days 1 to 3010.25 mg a week, weeks 1 to 41
Dose steps4 mg (days 31 to 60), 9 mg (days 61 to 90)10.5 mg, 1 mg, 1.7 mg, 4 weeks each1
Maintenance dose25 mg a day from day 9112.4 mg (recommended) or 1.7 mg from week 17; up to 7.2 mg for weight in adults who tolerate 2.4 mg for 4 weeks1
Strengths1.5, 4, 9 and 25 mg tablets1Single-dose pens 0.25 to 7.2 mg, syringes, a 4-dose FlexTouch pen1
Missed doseSkip it; next tablet the following day1Take it if the next dose is more than 2 days away, else skip1
StorageRoom temperature, original bottle1Refrigerator; up to 28 days at 46°F to 86°F before the cap comes off1
Approved forWeight and heart risk, adults only1Weight (adults and age 12+), heart risk, MASH1
Two dose ladders on one time axis: the pill steps 1.5, 4, 9 and 25 mg a day at days 1, 31, 61 and 91; the shot steps 0.25, 0.5, 1, 1.7 and 2.4 mg a week at weeks 1, 5, 9, 13 and 17 (day 113)
The pill reaches its maintenance dose at day 91, the shot at week 17.

The label lets people switch at the top doses: the 25 mg tablet starts one week after the last 2.4 mg shot, and the 2.4 mg shot starts the day after the last 25 mg tablet; for someone who does not tolerate 25 mg, it suggests the 1.7 mg weekly shot1. These are the label's schedules, not a plan for one person: the dose and any change are the prescriber's decision. The full injection schedule is in our guide to Wegovy and Ozempic dosage, and the GLP-1 titration calculator lays a schedule out by date.

How much weight did people lose on the pill, and on the shot?

The pill's weight trial is OASIS 4: 307 adults with obesity, or overweight and a related condition, without diabetes, given 25 mg a day or placebo for 64 weeks, the first 12 spent climbing to the full dose13. The shot's main trial is STEP 1: 1,961 adults with the same entry rules, given 2.4 mg a week or placebo for 68 weeks14. The label prints both results the same way, counting everyone who started, including those who stopped the drug1:

ResultOASIS 4: pill, 25 mg dailySTEP 1: shot, 2.4 mg weekly
People (drug / placebo)205 / 10211,306 / 6551
Starting weight, average106.4 kg (235 lb)1105.4 kg (232 lb)1
Length of treatment64 weeks168 weeks1
Average weight change−13.6%, against −2.4% on placebo1−14.9%, against −2.4% on placebo1
Lost at least 5%76.3% of people, against 31.3%183.5%, against 31.1%1
Lost at least 10%59.8%, against 14.4%166.1%, against 12.0%1
Lost at least 15%47.0%, against 5.5%147.9%, against 4.8%1
Lost at least 20%27.9%, against 3.1%130.2%, against 1.7%1
Shares losing at least 5, 10, 15 and 20% of weight: OASIS 4 pill 76.3, 59.8, 47.0 and 27.9% against placebo 31.3, 14.4, 5.5 and 3.1%; STEP 1 shot 83.5, 66.1, 47.9 and 30.2% against 31.1, 12.0, 4.8 and 1.7%
Compare each drug bar with its own placebo: these are two trials, not one head-to-head.

Side by side, the two land close: 11.2 and 12.4 points beyond placebo. They are separate trials, not a head-to-head test, so the table shows two results, not a winner. The OASIS 4 paper's own analysis puts placebo at −2.2% and the gap at 11.4 points3; STEP 1's paper reports a 15.3 kg average loss4. Neither trial enrolled people with type 2 diabetes, and in type 2 diabetes the tablet gives lower blood levels than the shot (next section), so the label names a switch to the 1.7 mg shot when more weight loss is needed1.

Is a daily pill as strong as a weekly shot?

In the blood, roughly, yes. Semaglutide's half-life is about one week either way, so daily tablets pile up into a steady level, reached after 4 to 5 weeks on a dose12. On the label's estimates the average level is about the same: around 77 nmol/L on the 25 mg tablet and 75 nmol/L on the 2.4 mg shot in people with overweight or obesity1. The difference is the spread: 90% of people on the tablet sat between 27 and 186 nmol/L, against 51 to 110 nmol/L on the shot1. In type 2 diabetes the tablet's average is lower, about 44 nmol/L against 68 on the shot1.

The chart shows the level building over a month for weekly semaglutide, the shot. The tablet builds toward a similar plateau in small daily steps rather than one weekly one, and after the last dose semaglutide stays in the blood for about 5 to 7 weeks either way1.

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleSemaglutide in the library

What are Rybelsus and Ozempic tablets?

They are the other semaglutide tablets, and both are for type 2 diabetes, not weight. Rybelsus was approved on September 20, 2019; Ozempic tablets were added to the same application on January 30, 20266. They share one label, approved to improve blood sugar in adults with type 2 diabetes and to lower heart risk in those at high risk2.

The milligrams do not match across brands, and the label says the two are not substitutable mg for mg2. Rybelsus comes as 3, 7 and 14 mg; Ozempic tablets as 1.5, 4 and 9 mg, the strengths and the two inactive ingredients (SNAC and magnesium stearate) of the Wegovy pill's first three steps12. About 0.4% to 1% of a Rybelsus tablet is absorbed, against 1% to 2% of an Ozempic tablet, and in healthy volunteers 3, 7 and 14 mg of Rybelsus gave blood levels no meaningfully different from 1.5, 4 and 9 mg of Ozempic tablets2. So the label pairs 7 mg with 4 mg, and 14 mg with 9 mg, for a switch after the first month2. The morning rule is the same for all of them2, and the Wegovy label advises against combining it with any other semaglutide or GLP-1 medicine1.

What side effects come with the pill?

The same kind as the shot's: the label says the common side effects on the 25 mg tablets were similar in type and frequency to the injection's, mostly stomach effects1. In OASIS 4, 74.0% on the tablet had a stomach side effect at some point, against 42.2% on placebo3, and 6.9% stopped because of side effects, against 5.9%1. Like the shot, the tablet carries a boxed warning because semaglutide caused thyroid C-cell tumors in rodents; the label says it is unknown whether it does in humans1. Rates by dose and what helps are in our guide to Ozempic and Wegovy side effects.

When to get help Severe stomach pain that does not ease, sometimes reaching the back, is the label's sign to stop the tablets and call a doctor1.

Commonly reported: the morning routine is the hardest part at first, with the wait before coffee the usual complaint; nausea or fullness in the first days after each monthly step; and appetite going quiet within the first weeks, much as people describe on the shot.

Track it in the app

Sources

  1. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets prescribing information, DailyMed, June 2026 dailymed.nlm.nih.gov
  2. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets prescribing information, DailyMed, January 2026 dailymed.nlm.nih.gov
  3. Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025. PubMed 40934115
  4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
  5. Drugs@FDA: NDA 218316, WEGOVY tablets, original approval December 22, 2025 accessdata.fda.gov
  6. Drugs@FDA: NDA 213051, RYBELSUS and OZEMPIC tablets (original approval September 20, 2019; supplement 30, January 30, 2026) accessdata.fda.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo